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Abstract: Bacteremia is associated with high morbidity and mortality. Improving prevention 
and treatment requires better knowledge of the disease and its prognosis. However, in order 
to study the entire spectrum of bacteremia patients, we need valid sources of information, 
prospective data collection, and complete follow-up. In North Denmark Region, all patients 
diagnosed with bacteremia have been registered in a population-based database since 1981. 
The information has been recorded prospectively since 1992 and the main variables are: the 
patient’s unique civil registration number, date of sampling the first positive blood culture, date 
of admission, clinical department, date of notification of growth, place of acquisition, focus of 
infection, microbiological species, antibiogram, and empirical antimicrobial treatment. During 
the time from 1981 to 2008, information on 22,556 cases of bacteremia has been recorded. The 
civil registration number makes it possible to link the database to other medical databases and 
thereby build large cohorts with detailed longitudinal data that include hospital histories since 
1977, comorbidity data, and complete follow-up of survival. The database is suited for epide-
miological research and, presently, approximately 60 studies have been published. Other Danish 
departments of clinical microbiology have recently started to record the same information and 
a population base of 2.3 million will be available for future studies.
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Introduction
Bacteremia is a clinical entity associated with detection of one or more micro-organisms 
in the blood, usually by culturing techniques. The entry of bacteria or fungi into the 
bloodstream can occur as a primary event that may lead to secondary infection of deep-
sited organs and tissues or at a later stage if the pathogens are not contained at the site 
of infection by host defense mechanisms.1 Accordingly, the presence of viable micro-
organisms in the circulating blood depends both on the capacity of micro-organisms 
to evade host defenses and on the competence of the patient’s immune system.
A number of cohort studies have confirmed the prognostic impact of bacteremia 
and fungemia,2,3 but the majority of the current studies are limited to one species or 
group of micro-organisms. Therefore a prospective recording of all patients with 
bacteremia and fungemia was started in North Jutland, Denmark in 1992 and in 1996 
this became The North Denmark Bacteremia Research Database.
An historical perspective of bacteremia research
The term bacteremia was coined in the 19th century when bacteria and fungi were 
placed within the same taxonomic group.4 Since, generically, bacteremia includes 
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both bacteria and fungi, we use the term accordingly in this 
review. Studies of bacteremia have a longstanding tradition.5,6 
In particular, Streptococcus pneumoniae,7 Staphylococcus 
aureus,8,9 and enteric Gram-negative rods10–12 have been stud-
ied extensively. In the 1970s and early 1980s, a number of 
thorough clinic-based outcome studies were conducted5,13,14 
and two of the most influential papers on bacteremia were 
published by Weinstein et al in 1983.15,16 These twin papers 
included a detailed set of definitions that became a foundation 
for later research, including this database.
Information on bacteremia
Laboratory information systems can be used to identify 
patients with specific microbial agents or well defined groups 
thereof. However, when the entire spectrum of bacteremia is 
studied, the use of these data sources is more cumbersome, 
with the main challenge being distinction of the individual 
episodes. Information on bacteremia can also be retrieved 
from hospital discharge registries, but the codes vary between 
versions of the International Classification of Diseases and the 
sensitivity and specificity of the registration may be low.17–19 
Moreover, important microbiological information can be 
lost during the coding process. Combined microbiological 
and clinical databases dedicated to patients with bacteremia 
may overcome many of these problems. To our knowledge, 
the first databases that included all types of bacteremia were 
developed at St Thomas’s Hospital, London, England20,21 and 
at Beilinson Hospital, Petah Tiqva, Israel.22,23 Both databases 
are clinic-based, however, and epidemiological studies can 
only be generalized with caution. In 1991, physicians at 
Aalborg Hospital in North Jutland, Denmark, used archived 
blood culture reports from the years 1981–1991 to establish 
a cohort of bacteremia patients.24 This led to the development 
of a population-based bacteremia database with prospectively 
collected data. Although the initial aim was to improve the 
clinical service,25 it was realized that the data collected pre-
sented a considerable research potential.26
Setting and study population
“Of all the microbiological procedures performed in the 
laboratory, few are as important as the prompt recovery of 
micro-organisms from blood”.27 This citation highlights the 
important clinical implications of blood cultures.28 Still, the 
diagnosis requires teamwork between the physician who is 
in charge of the patient and the diagnostic laboratory that 
processes the blood cultures and provides the microbiological 
information. In Denmark, physicians in the departments of 
clinical microbiology take care of the notification of attending 
physicians, render advice on antibiotic therapy, and search 
for the focus of infection. This service makes the distinction 
between contaminants and significant blood culture isolates 
more straightforward.15
Since 1992, the information obtained during these 
consultations has routinely been recorded in a structured 
format at the Department of Clinical Microbiology, Aalborg 
Hospital, which provides diagnostic microbiology to both 
general practitioners and public hospitals in the local health 
region (Table 1). The health region consists of mixed rural 
and urban areas with a modestly growing population. The 
Danish tax-paid health care system provides access, free of 
charge, to primary care by general practitioners as well as sec-
ondary and tertiary care in public hospitals. Currently, there 
are eight public hospitals in the region. Aalborg Hospital, an 
800-bed university hospital, is the region’s referral hospital 
and serves as district hospital for the city of Aalborg. Patients 
in need of highly specialized treatment, including solid organ 
transplantation, are referred to one of three national centers 
outside the region.
Microbiological methods
Several improvements of the blood culture technique have 
been implemented over the years,29–31 the most important 
being the introduction of a commercial broth culture system 
(Colorbact, Statens Serum Institut, Copenhagen, Denmark) 
in 1992.30 In 1996 this system was replaced by the auto-
Table 1 health region covered by the population-based North 
Denmark Bacteremia Research Database and associated hospital 
statistics
Year County of North Jutland North 
Denmark 
Regiona
1981 1992 2006 2007
Area 6173, km2 6173, km2 6173, km2 7927, km2
Population 481,501 485,787 495,090 576,972
Number of 
hospitals
11 10 6 8
Number of 
bed days
746,110 550,916 483,646 526,917
Number of 
admissions
82,334 95,344 103,866 120,000
Number of 
blood 
cultures
3,327 8,916 17,047 b
Number of 
bacteremias
368 671 1107 b
Notes: aNorth Jutland County became part of the larger North Denmark Region 
from January 1, 2007. bThe years 2007–2009 encompassed a transitional period in 
which the clinical microbiological service did not include the region’s new hospitals. 
From 2010, the bacteremia database will again have full population-based coverage. Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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mated BacT/Alert® system (bioMérieux, Marcy l’Etoile, 
France).29,31 Each blood culture set includes two aerobic and 
one anaerobic bottle; for children up to 4 years of age, one 
pediatric bottle is used.
Positive blood cultures are subcultured and identified by 
a combination of conventional and commercial methods as 
previously described.24,32 Isolates likely to be contaminants 
according to the criteria set by Weinstein et al15 are submit-
ted to a less extensive workup. Bacteria and fungi listed for 
national surveillance are referred to Statens Serum Institut, 
Copenhagen, together with unidentified micro-organisms. 
Pneumococcal serotypes, meningococcal serogroups/sero-
types/serosubtypes, as well as S. aureus phage types (recently 
replaced by spa types), are obtained with courtesy of Statens 
Serum Institut. Molecular typing is rarely done, but isolates 
of the same species with a unique biochemical profile or 
antibiotic susceptibility pattern (antibiogram) are reported 
separately.33 Blood culture isolates, with the   exception of 
contaminants, have been stored in glycerol broth at -80°C 
since 1995.
Data collection and variables
Definitions
Despite extensive literature on bacteremia, there was no 
coherent set of definitions on which a database could be 
based in 1992. We therefore developed a set of definitions, 
inspired by earlier clinic-based studies.10,12,15,16,34–36 We define 
the date on which the first positive blood culture is drawn as 
the start of bacteremia (T0) and the baseline of follow-up. 
In patients with multiple positive blood cultures, we use 
one or more of the following criteria to distinguish a new 
episode: 1) a blood culture isolate that differs from the previ-
ous with regard to species and/or antibiogram, 2) a different 
focus of infection, or 3) an interval of at least 30 days 
between two positive blood cultures. We define polymi-
crobial bacteremia as an episode with two or more blood 
culture isolates of different species or antibiogram obtained 
within 48 hours. However, similar to Roberts,37 an exception 
to this is made for patients with a second isolate obtained 
within 25–48 hours if there is evidence of another focus of 
infection (eg, related to catheterization or surgery).
The focus is defined as the organ or tissue infected at 
the time when bacteremia becomes clinically apparent and 
a blood culture is drawn.38 Determining the focus is based 
on all microbiological and clinical evidence obtained during 
admission, including imaging studies. We do not distinguish 
between primary and secondary foci because this spread is 
rarely observed clinically.
The US Centers for Disease Control and Prevention 
(CDC) surveillance definitions of bacteremia pertain 
primarily to nosocomial infections39 and bacteremias are 
categorized as community-acquired if there is clinical 
evidence that the infection was present or incubating at the 
time of admis  sion. We do not use a fixed time limit (eg, 48 
or 72 hours) to   distinguish between community-acquired 
and nosocomial bacteremias because such a criterion is 
not specified in the CDC guideline.39 Since 1992, we have 
considered patients with a hospital stay within 30 days prior 
to admission or who have regular hospital visits (eg, for 
hemodialysis or chemotherapy) as belonging to a separate 
‘health care-associated’ group.40,41 This 30-day period is in 
agreement with   Siegman-Igra et al.41 Others have chosen a 
period from 90 days to more than one year after a hospital 
stay in order to accommodate for long-term carriage of mul-
tiresistant pathogens such as methicillin-resistant S. aureus 
(MRSA).42–44 However, in our opinion, the categorization of 
health care-associated bacteremia should primarily account 
for a temporary impairment of the patient’s health related to 
the previous condition.
We consider antibiotic treatment given at the first 
  notification as empirical and categorize it as appropri-
ate if administered intravenously (with exception of 
  fluoroquinolones and metronidazole) and if blood isolates are 
susceptible to one or more antibiotics given. If one or more 
isolates are resistant, or if the dose/route of administration 
is inadequate, treatment is categorized as inappropriate. An 
annually updated national Danish guideline serves as a refer-
ence for antibiotic dosing.45,46
Informatics
From the outset, data were recorded in an SQL database 
(Paradox, Borland International, Scotts Valley, CA). Since 
1996, North Jutland County has managed the database 
within the informatics framework of the health region. 
Transfer of data to a web server (Microsoft® Corp., 
Redmond,WA) has facilitated a partial integration with the 
microbiological laboratory information system (ADBakt 
and WWBakt, Autonik,   Sweden) and the patient adminis-
trative system (PAS, Logica A/S, Denmark). Through the 
later system, the database is updated with information on 
vital status for residents in North Denmark Region and the 
neighboring Central Denmark Region. Since 2006, physi-
cians have recorded the clinical information directly into the 
laboratory information system; eventually the bacteremia 
research database and the laboratory information system 
may become fully integrated. Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Variables
Main variables recorded include: civil registration number; 
date of admission; clinical department; date and hour of 
venipuncture for the first positive blood culture (T0); date 
and hour of the first notification of the attending physi-
cian; detection time in hours; a variable differentiating 
community-acquired, health care-associated, and nosoco-
mial bacteremia (1992 onwards); focus of infection (from 
1992); microbiological species; antibiogram; empirical 
and recommended antibiotic therapy; and appropriateness 
of antimicrobial treatment (from 1992). Table 2 provides a 
complete list of the fields recorded in the database for each 
bacteremic episode.
Time period
All patients diagnosed with bacteremia since January 1, 
1981 are registered in the database; data covering 1981 to 
1991 was collected retrospectively from archived blood 
culture reports, but since 1992 the information has been 
recorded concurrently with the clinical episode. Between 
1981 and 2008, 22,556 cases have been recorded (5114 
[23%] from 1981–1991, 15,062 [67%] from 1992–2006, 
and 2380 [11%] from 2007–2008). Figure 1 shows a modest 
increase in annual numbers from 1981 to 1991, followed 
by a steep rise up to 2004. The time from 2007 to 2009 
represents a transitional period for which we do not have 
full population-based coverage in the new North Denmark 
Region.
Methodological aspects
Strengths and weaknesses
The database covers all patients diagnosed with bacteremia 
in North Denmark Region and that it incorporates a complete 
register-based follow-up for mortality is one of the major 
strengths. Use of the civil registration number assigned to 
all Danes makes it possible to link bacteremia data to other 
medical and socioeconomic Danish registries including the 
Danish National Registry of Patients (with data on all hos-
pital admissions and discharge diagnoses since 1977 and all 
outpatient visits since 1995), the Danish Civil Registration 
System (which contains data on immigration, emigration, 
and death), the Prescription Database for North Denmark 
Region (which retains key information on prescriptions 
for reimbursable drugs dispensed from pharmacies), and a 
clinical biochemistry database (LABKA, CSC Scandihealth, 
Denmark, which holds data recorded since 1997 for patients 
both in primary and hospital care). This makes it possible 
to build large cohorts with detailed longitudinal data that 
include full hospitalization history, comorbidity data, and 
complete long-term follow-up data. The population base 
makes the database especially suited for matched cohort   studies 
of community-acquired bacteremias. The Danish Civil Reg-
istration System facilitates the selection of controls from the 
underlying population using incidence density sampling.47,48
Table 2 List of the fields recorded in the database for each 
bacteremic episode
Unique bacteremia episode number
The patient’s 10 digit personal civil registry number
Age
Sex
Clinical department (at time of venipuncture)
Clinical speciality
Date of admission
Transfer (including from nursing home)
Laboratory identification number of sentinel blood culture 
Time of the venipuncture (date and hour)
Time of first notification (date and hour)
Number of positive blood culture bottles
Number of blood culture bottles inoculated
Focus of infection
Evidence to support the focus: clinical (including imaging) (y/N)
Evidence to support the focus: microbiological (y/N)
Evidence to support the focus: pathoanatomic (y/N)
Microbiological specimens other than blood (y/N)
Place of acquisition
Date of death
Alive day 30 (y/N)
Alive day 180 (y/N)
Accessory clinical information:
Chronic urinary catheter 
Intravenous line 
Permanent intravenous catheter
Chronic urinary catheter
Surgical procedure (y/N)
Trauma patient (y/N)
Comorbid diseases (Y/N) 
  Solid cancer  
  hematological cancer 
  Liver cirrhosis 
  Diabetes mellitus 
  Renal failure 
  Dialysis
Cumulative number of bacteremic episodes (1, 2, 3, ….)
Number of blood culture isolates
Relation: Antibiotic therapy
Antibiotic(s) given at first notification
Antibiotic(s) recommended at first notification
Appropriateness of empirical antibiotic therapy
Antibiotic(s) given at second notification
Antibiotic(s) recommended at second notification
Relation: Blood culture isolate number: #
Species
Type (serotype, serogroup, phage type, spa type, etc)
Relation: Antibiotic susceptibility (SIR) of blood culture isolate number: #
Antibiotic (up to 24 antibiotics)
Abbreviation: SIR, susceptible-indeterminate-resistant. Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Furthermore, we consider both the concurrent record-
ing of information and the strict definitions to be advanta-
geous. The definition most important for the number and 
pattern of bacteremias is probably the duration of the 
bacteremic episode. In the literature, the duration varies 
from 2 to more than 30 days15,49–52 and although a 30-day 
limit is arbitrary, it should allow time for treatment of the 
underlying focus and clinical recovery. Moreover, positive 
blood cultures obtained within this period are likely due 
to either ineffective antibiotic therapy or an unresolved 
focus of infection and do rarely constitute an entirely new 
clinical episode.
Finally, efforts are continuously made to validate the 
bacteremia information recorded in the database and there 
is very little missing data.
The main weakness of the database is the lack of clinical 
data on acute disease severity including SIRS criteria,53 as 
well as other clinical scores. We hope that implementation 
of electronic medical records will allow more detailed char-
acterization of patients with bacteremia and their treatments 
for future studies.
Research from the database
The predominant research themes have been the risk and 
outcome of bacteremia. In the study of community-acquired 
bacteremia, we were among the first to use the Charlson 
Index to adjust for comorbidity.31 Quite early, we also became 
interested in the long-term prognosis of bacteremia.54,55
A study from 1999 described the secular trends in 
  incidence and mortality of bacteremia in North Jutland 
County during 1981 to 1994.30 During that period the 
incidence increased by 100% (from 76 to 153 per 100,000 
person-years), whereas the 30-day case fatality rate remained 
stable (23.6%, 95% confidence interval [CI]: 22.6–24.6).
Another priority has been to address bacteremia in 
patients with prevalent diseases such as liver cirrhosis,56 
alcohol abuse,57 diabetes mellitus,47,58 and hematological 
malignancies.59,60 Thomsen et al47 found that patients with dia-
betes had a substantially increased risk for bacteremia caused 
by enteric Gram-negative rods (adjusted odds ratio [OR] 2.9, 
95% CI: 2.4–3.4). Among patients with bacteremia, diabetes 
was also associated with a poorer prognosis (adjusted mortal-
ity rate ratio [MRR] 1.3, 95% CI: 0.9–1.8).
Recently, we used the bacteremia database to describe 
the impact of age and comorbidity on short-term mortality 
from community-acquired bacteremia.61 We found older 
age and greater comorbidity to be associated with higher 
30-day mortality. Thirty-day mortality rates increased from 
11% in patients younger than 65 years to 21% in patients 
aged 80 years and older. Likewise, the 30-day mortality rate 
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in patients with low comorbidity was 7% but increased to 
23% in patients with high comorbidity.61 We further found 
that increasing age-related comorbidity did not explain the 
effect of age. This prognostic effect of age on short-term 
bacteremia mortality has also been demonstrated in patients 
with hematological malignancies.62
The database has further been used to study trends in anti-
biotic resistance24,32 and antibiotic treatment of bacteremia.63 
Pedersen et al64 showed that antibiotic treatment within 
90 days prior to admission was associated with antibiotic-
resistant blood culture isolates in patients with community-
acquired bacteremia; this observation is important because 
the impact of antibiotic treatment on resistance is rarely 
studied in patients with systemic community-acquired infec-
tions. From 1999 to 2003, an international working group 
used data both from the Danish and the aforementioned 
Israeli bacteremia database to develop a medical decision 
support system for antibiotic treatment.65,66
Access for other researchers
The database is public and researchers with permission 
from the Danish Data Protection Agency will be granted 
access to the data. Moreover, we would be interested in 
collaborating with external research institutions under the 
provisions of the Data Protection Agency. Data files are 
kept for research purposes by the Department of Clinical 
  Epidemiology, Aarhus University, while the original data 
files are kept by the North Denmark Region. Potential 
collaborators are invited to contact the corresponding 
author.
Perspectives
Knowledge of the occurrence and outcome of bacteremia 
is important to establish its burden of illness to guide 
appropriate allocation of limited health care and research 
resources. Population-based studies are optimal to describe 
the epidemiology of bacteremia because the well defined 
catchment area allows determination of incidence rates and 
risk factors. However, our knowledge about preventable or 
modifiable risk factors and prognostic factors for bacteremia 
in a population-based setting remains limited. We hope 
that in the future, joint efforts by researchers in disciplines 
including clinical epidemiology, molecular epidemiology and 
pharmaco-epidemiology, clinical microbiology, infectious 
diseases, and clinical medicine will provide new insights into 
the etiology, course, and prevention of bacteremia. Future 
work may also uncover potential sources of infection and 
reservoirs in humans, animals, and nature.67
The continuous development of the North Denmark 
Bacteremia Research Database is a priority and includes 
full integration with departmental and hospital information 
systems. The database has inspired interregional coop-
eration on bacteremia research and key information on 
bacteremia cases is currently recorded in the same format 
by three Danish departments of clinical microbiology on a 
routine basis.68 This holds promise of a population base of 
approximately 2.3 million inhabitants for future bacteremia 
studies.
Other regions worldwide have reported on population-
based bacteremia data including Australia, Canada, Iceland, 
Finland, and the United States. Recently, an international 
collaboration was established that represents six regions in 
four countries on three continents with a combined annual 
surveillance population of more than 8 million residents.69 
This collaboration will facilitate comparison of interregional 
differences in incidence, risk factors, outcomes, and resis-
tance rates. Moreover, the large surveillance population 
allows the study of rare isolates and assists early detection 
of emerging pathogens. Finally, the recognition of the impor-
tance of global trade and international travel in the spread 
of multiresistant organisms has highlighted that infectious 
disease control is a global concern.70
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